-
In the past week, multiple securities law firms, including Robbins Geller Rudman & Dowd LLP and Rosen Law Firm, announced class action lawsuits against PROCEPT BioRobotics, alleging undisclosed discounting practices that inflated reported U.S. handpiece sales and conflicted with prior guidance between February 2024 and February 2026.
-
The lawsuits focus on claims that PROCEPT's bulk-order discount program pulled sales forward, left more than 10,000 excess handpiece units in the field, and exposed investors to previously undisclosed operational and financial risks tied to inventory imbalances.
-
We'll now examine how allegations around undisclosed discounting and excess field inventory could reshape PROCEPT BioRobotics' previously optimistic investment narrative.
Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge .
PROCEPT BioRobotics Investment Narrative Recap
To own PROCEPT BioRobotics, you ultimately have to believe Aquablation can grow into a durable, procedure-driven franchise, with expanding system placements and recurring handpiece use. The new class action lawsuits cut directly into that story in the near term, because they question how much of past handpiece demand was pulled forward through discounting and how exposed the business might be to slower unit sales as excess inventory works down.
The most relevant recent announcement here is the July 24, 2026 update on the securities class action, which details alleged bulk-order discounting, a build-up of more than 10,000 excess handpieces, and missed 2025 guidance. Against catalysts like HYDROS expansion and stronger guideline support, this legal overhang adds a fresh layer of uncertainty around reported growth quality, future guidance, and how quickly Aquablation usage can normalize once field inventory is addressed.
But beneath the growth story, investors should also be aware of how undisclosed discounting, excess inventory and ongoing losses could together...
Read the full narrative on PROCEPT BioRobotics (it's free!)
PROCEPT BioRobotics' narrative projects $608.2 million revenue and $77.8 million earnings by 2029. This requires 23.6% yearly revenue growth and a $180.3 million earnings increase from -$102.5 million today.
Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value , a 70% upside to its current price.
Exploring Other Perspectives
Before this news, the most cautious analysts already assumed about 23.5 percent annual revenue growth to around US$607.0 million by 2029, yet saw profitability and margin pressure risks very differently, reminding you that informed views can vary widely and may shift again as these discounting and inventory allegations are resolved.
Explore 7 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth over 2x more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
-
A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
-
Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.
Contemplating Other Strategies?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
-
Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
-
Find 48 companies with promising cash flow potential yet trading below their fair value .
-
Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PRCT .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
